Adaptimmune Therapeutics plc (ADAP)

Adaptimmune Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	116.74	143.99	108.03	149.95	56.88	50.41
Short-Term Investments	69.35	2.95	96.57	219.63	311.34	39.13
Cash & Short-Term Investments	186.09	146.94	204.61	369.58	368.22	89.54
Cash Growth	15.06%	-28.18%	-44.64%	0.37%	311.22%	-56.35%
Accounts Receivable	12.5	0.82	7.44	0.75	0.14	-
Other Receivables	-	46.1	30.65	33.26	20.95	19.28
Receivables	12.5	46.92	38.09	34.01	21.09	19.28
Inventory	1.87	1.33	1.28	0.75	2.09	1.46
Prepaid Expenses	-	9.95	9.47	9.04	6.31	8.4
Other Current Assets	43.75	2.41	1.93	2.08	0.44	1.81
Total Current Assets	244.21	207.55	255.37	415.46	398.15	120.49
Property, Plant & Equipment	65.29	71.71	71.54	51.37	46.66	51.86
Other Intangible Assets	4.28	0.33	0.44	1	1.73	2.2
Other Long-Term Assets	3.65	3.03	1.57	1.72	4.6	7
Total Assets	317.44	282.62	328.92	469.55	451.14	181.54
Accounts Payable	9.07	8.13	4.75	8.11	6.39	6.36
Accrued Expenses	31.5	28.85	29.06	29.58	27.03	23.31
Current Portion of Leases	4.18	5.38	2.73	2.32	2.77	2.49
Current Income Taxes Payable	-	1.4	-	-	-	-
Current Unearned Revenue	18.71	28.97	23.52	22.2	2.83	2.13
Other Current Liabilities	-	0.05	4.44	0.33	0.05	0.06
Total Current Liabilities	63.46	72.79	64.5	62.54	39.07	34.34
Long-Term Leases	20.46	19.85	20.35	23.15	20.94	22.97
Long-Term Unearned Revenue	98.73	149.06	160.89	177.22	49.26	-
Other Long-Term Liabilities	4.94	1.4	1.3	0.67	0.64	0.6
Total Liabilities	237.45	243.1	247.04	263.59	109.92	57.91
Common Stock	2.08	1.87	1.4	1.34	1.33	0.94
Additional Paid-In Capital	1,103	1,065	990.66	959.61	935.71	585.62
Retained Earnings	-1,020	-1,023	-909.3	-743.85	-585.76	-455.66
Comprehensive Income & Other	-5.14	-3.75	-0.88	-11.14	-10.05	-7.26
Shareholders' Equity	79.99	39.51	81.88	205.96	341.23	123.64
Total Liabilities & Equity	317.44	282.62	328.92	469.55	451.14	181.54
Total Debt	74.5	25.24	23.08	25.47	23.71	25.46
Net Cash (Debt)	111.6	121.7	181.53	344.11	344.51	64.08
Net Cash Growth	-18.02%	-32.96%	-47.25%	-0.11%	437.59%	-68.76%
Net Cash Per Share	0.45	0.61	1.13	2.21	2.42	0.61
Filing Date Shares Outstanding	255.88	246.83	165.31	156.73	155.14	130.08
Total Common Shares Outstanding	255.81	227.17	164.52	156.26	154.79	105.17
Working Capital	180.76	134.76	190.87	352.92	359.08	86.15
Book Value Per Share	0.31	0.17	0.50	1.32	2.20	1.18
Tangible Book Value	75.71	39.18	81.44	204.96	339.5	121.44
Tangible Book Value Per Share	0.30	0.17	0.49	1.31	2.19	1.15
Machinery	-	38.97	34.92	32.65	30.52	27.4
Construction In Progress	-	0.05	28.73	5.4	-	-
Leasehold Improvements	-	57.94	28.46	28.7	28.36	27.32

Source: S&P Capital IQ. Standard template. Financial Sources.